Nexalin Technology (NXL) Operating Income (QoQ) (2021 - 2026)
Nexalin Technology (NXL) Operating Income (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn |
| 10 | Nexalin Technology | 6.98 Mn | 5.97 Mn | 8,897.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.01% |
| Mar 31, 2026 | 12.15% |
| Dec 31, 2025 | -2.88% |
| Sep 30, 2025 | -44.72% |
| Jun 30, 2025 | 19.41% |
| Mar 31, 2025 | 30.05% |
| Dec 31, 2024 | -14.63% |
| Sep 30, 2024 | -93.41% |
| Jun 30, 2024 | -20.80% |
| Mar 31, 2024 | 33.90% |
| Dec 31, 2023 | 32.75% |
| Sep 30, 2023 | -175.48% |
| Jun 30, 2023 | -12.50% |
| Mar 31, 2023 | -8.31% |
| Dec 31, 2022 | -145.44% |
| Sep 30, 2022 | 34.13% |
| Jun 30, 2022 | -18.66% |
| Mar 31, 2022 | 35.04% |
| Dec 31, 2021 | 67.84% |